Tofatas Ointment 2% — Tofacitinib Topical Ointment, 15 g

Tofatas is supplied as an ointment for external use, featuring a refined lipophilic base designed for deep transcutaneous delivery of the active ingredient:

• Presentation and Packaging: 1 original laminated aluminum tube containing 15 g of topical ointment. The tube is packed in a cardboard box with tamper-evident seals, an IN Quality security hologram, and a comprehensive package insert.
• Active Ingredient:
  • Tofacitinib — 2% w/w (equivalent to 20 mg of tofacitinib per 1 gram of ointment).
• Excipients: White soft paraffin, liquid paraffin, cetostearyl alcohol, propylene glycol, polysorbate 60, sorbitan stearate, dimethicone, benzyl alcohol, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), purified water.

Pharmacodynamics: Tofacitinib is a partial and selective inhibitor of the Janus kinase enzyme family (primarily JAK1 and JAK3, with lesser inhibition of JAK2). Intracellular Janus kinases transduce signals from cytokine receptors via the STAT pathway. By inhibiting STAT phosphorylation and activation, Tofatas downregulates pro-inflammatory gene expression. In Alopecia Areata, the ointment abolishes T-cell infiltration around the hair bulb; in Vitiligo, it blocks the IFN-gamma/CXCL10 signaling cascade, preventing melanocyte destruction.

Pharmacokinetics: Following topical application of Tofatas 2% ointment to intact or affected skin, the active component penetrates into the stratum corneum, epidermis, and upper dermis. Systemic bioavailability of tofacitinib via transdermal absorption is minimal (less than 1–3% of the applied dose depending on application area and skin barrier integrity). The small fraction entering systemic circulation is metabolized in the liver mainly via the CYP3A4 pathway and eliminated via renal and fecal routes.

Tofatas is indicated for the topical treatment of adult and adolescent patients with the following dermatological conditions:

• 🔹 Alopecia Areata: Treatment of patchy, subtotal, and total autoimmune hair loss affecting the scalp, eyebrows, and beard area.
• 🔹 Vitiligo: Therapy for non-segmental and segmental vitiligo to promote repigmentation of depigmented skin patches.
• 🔹 Atopic Dermatitis: Monotherapy or adjunctive therapy for moderate-to-severe atopic dermatitis when topical corticosteroids (TCS) are inadequate or contraindicated.
• 🔹 Plaque Psoriasis: Localized management of plaque psoriasis to reduce erythema, skin induration, and scaling.

Application of Tofatas ointment should follow the guidance of a qualified dermatologist:

• 👨‍⚕️ Dosing Regimen:
  • Apply a thin layer of ointment to clean, dry affected skin areas 2 times daily (morning and evening), approximately 12 hours apart.
• 👨‍⚕️ Application Technique: Gently rub the ointment into the skin until fully absorbed. Wash hands thoroughly with soap after application (unless treating hand lesions).
• 🥤 Duration of Treatment: Treatment duration depends on clinical response. For vitiligo and alopecia, initial clinical signs of improvement (repigmentation, vellus hair regrowth) are typically evaluated after 8–12 weeks of continuous use.

Tofatas ointment is strictly contraindicated in patients with the following conditions:

• ❌ Hypersensitivity or known allergic reaction to tofacitinib or any excipient in the ointment base.
• ❌ Active bacterial, viral (including herpes simplex and herpes zoster), fungal, or tuberculous skin infections at the application site.
• ❌ Open wounds, ulcers, severe skin erosions, or broken skin barriers at the treatment site.
• ❌ Pregnancy and the entire period of lactation.
• ❌ Pediatric patients under 12 years of age (due to insufficient safety and efficacy data).

Due to minimal systemic absorption, the risk of systemic drug interactions with Tofatas is low, but precautions should be observed:

• ⚠️ Concomitant Topical Agents: Do not apply Tofatas ointment simultaneously to the same skin site with other topical medications (corticosteroids, calcineurin inhibitors, or barrier creams) without allowing a 30-minute interval.
• ⚠️ Systemic Immunosuppressants: Combined use with oral immunosuppressive agents (methotrexate, cyclosporine, oral tofacitinib) requires careful clinical monitoring.
• ⚠️ Phototherapy (PUVA/UVB): Concomitant use with phototherapy should be planned with a dermatologist to avoid photo-irritation.

The use of Tofatas during pregnancy and lactation is restricted due to safety considerations:

• 🤰 Pregnancy: Systemic JAK inhibition may negatively impact embryo-fetal development. Tofatas is contraindicated during pregnancy. Women of childbearing potential should practice effective contraception.
• 🛡️ Family Planning: When planning pregnancy, treatment with Tofatas should be discontinued at least 4 weeks prior to intended conception.
• 🤱 Lactation: It is unknown whether topically applied tofacitinib is excreted in human milk. Breastfeeding should be discontinued during therapy.

Tofatas is generally well tolerated; however, localized or mild systemic adverse effects may occur:

• 🔴 Application Site Reactions: Mild burning sensation, pruritus, erythema, dryness, or irritation at the application site (usually transient).
• 🟡 Dermatologic Reactions: Acneiform eruptions, folliculitis, or localized hypertrichosis (at hair-loss treatment sites).
• 🟠 Local Infection Risks: Temporary local immune suppression may slightly increase susceptibility to superficial skin infections.
• 🟢 Systemic Effects (Rare): Mild headache or fatigue if applied over extensive body surface areas (>20% BSA).

Management and clinical approach in case of excessive application or accidental ingestion:

• Symptoms: Excessive topical application may increase local cutaneous irritation and redness. Accidental oral ingestion may cause gastrointestinal discomfort, nausea, or abdominal pain.
• Therapeutic Measures: In case of topical over-application, wipe off excess ointment with a dry tissue or wash with warm soapy water. If accidentally ingested, perform gastric lavage, administer oral adsorbents, and initiate supportive care.

Storage instructions for Tofatas ointment:

• Temperature Range: Store in a dry place protected from light at a temperature not exceeding 25 °C. Do not freeze.
• Packaging Integrity: Keep the tube tightly closed after each use to prevent the base from drying out.
• Safety: Store out of reach of children and pets.
• Shelf Life: 2 years (24 months) from the date of manufacture. Use within 3 months after first opening the tube.

Authentication guidelines for genuine Tofatas ointment manufactured by Intas Pharmaceuticals:

• Packaging & Graphics: The carton and tube feature Intas's signature design with green-and-red accent blocks. Text elements including Tofacitinib Ointment 2% w/w and Tofatas are crisply printed. Prominent labels include FOR EXTERNAL USE ONLY and net volume 15g.
• Batch Information: The crimp seal of the tube and the side flap of the box display embossed/laser-printed details: BATCH NO., MFG DATE, and EXP DATE.
• Security Hologram: The outer carton carries an official 3D security hologram bearing the IN Quality mark to verify authentic production by Intas Pharmaceuticals Ltd.